Sharon Bakalash, MD, PhD, CBA
Founder & CEO - SB Strategic Development Consultants
The event kicks off with a market overview followed by a highlight of several promising start-ups. We will conclude by navigating a deep-dive panel discussion with industry executives and host a live Q&A with select presenting companies.
Throughout the event you will have the ability to ask questions and make connections with other participants in real time.
PROUDLY SPONSORED BY:
Bausch + Lomb
Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, is one of the world's best-known and most respected health care brands, solely focused on protecting, enhancing and restoring people's eyesight.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for open-angle glaucoma, ocular surface diseases and retinal diseases. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie is expanding globally, with offices in Europe and Japan, and a manufacturing facility in Ireland. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% are approved in the EU. A Phase 3 study of netarsudil ophthalmic solution is underway in Japan, in collaboration with Santen. Aerie is also pursuing additional candidates in ophthalmology, including a Phase 2b dry eye program with AR-15512 (TRPM8 agonist), and two clinical-stage retina programs, AR-1105 (dexamethasone) Sustained Release Implant and AR-13503 (Rho kinase/Protein kinase C inhibitor) Sustained Release Implant. Aerie continues to investigate assets from its proprietary library of small-molecule multi-kinase inhibitors.
Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Through Surgical, Pharmaceutical and Vision Care, Alcon offers the world’s widest spectrum of ophthalmic products, helping millions of patients see the world better with clarity, color and beauty.
Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics.
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology. DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. YUTIQTM (fluocinolone acetonide intravitreal implant) 0.18 mg, was FDA approved on October 12, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.
Sun Ophthalmics is reenergizing eye care. We are a US division of Sun Pharma, a global specialty pharmaceutical corporation with operations in over 150 countries. Our mission is to launch innovative ophthalmic products that complement your approach to treatment. We focus on your unmet treatment needs in patient care so you can focus on your patients. Discover a brighter future in eye care. For more information on our products and vision, visit www.SunOphthalmics.com.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.